NanoViricides (NYSE: NNVC) is capturing investor attention as the company's leading drug candidate NV-387 prepares to enter Phase 2 clinical trials for MPox, a strategic step toward addressing both emerging viral threats and biodefense needs.
NV-387's novel nanoviricide technology not only neutralizes viruses before infection but also protects critical organs like the lungs, offering aunique therapeutic advantage over conventional antivirals.
Dual-track clinical plans, including basket-type trials for respiratory viruses, position NNVC to expand NV-387's utility across measles, influenza, RSV, and coronaviruses — a potential multi-billion-dollar antiviral market.
With a $7 valuation, Zacks Small Cap Research underscores NNVC's promising outlook, emphasizing NV-387's potential for strategic government procurement, orphan drug exclusivity, and BARDA funding.
NNVC's Phase 1 safety data, broad preclinical efficacy, and advanced clinical planning suggest an asymmetric upside for investors. With trials imminent and a clear path to regulatory milestones, NNVC stands ready to redefine antiviral therapy.
Positive results from the company's Phase 2 clinical trials for MPox could have immediate implications for FDA approval under the Animal Rule for Smallpox, unlocking a $1 billion market via the U.S. Strategic National Stockpile and potential BARDA funding — a major milestone for shareholder value!
Many owners would love a chance to own a piece of SpaceX. That explains the enthusiasm from Elon Musk’s announcement that he plans to go public sometime in 2026. According to Bloomberg, the initial public offering (IPO) may take place in "mid-to-late 2026," or it may slip into 2027.
Table of Contents
However, the SpaceX news is also a reminder that one of the best ways to invest in an IPO is by not investing in an IPO at all.
That's because investing in IPOs is a coin flip.
One of my favorite flops was the Ferrari IPO flop in 2015.
Here was a $12 billion IPO rolling on to the showroom floor, oversubscribed 10 times over. Investors were excited. Anticipation was high. The press noted it could be a hot runner even though the company had just said net profits fell 34%. Unfortunately, the IPO was a flop. Shares would plummet from $60 to $33 in days. Millions of dollars were wiped out.
However, investors can also find examples of Amazon-type IPOs that just explode out of the gate and keep running.
So which one of these scenarios is more likely for SpaceX?
There's the potential for Elon Musk's SpaceX to raise more than $25 billion in 2026, and would reportedly include Starlink, SpaceX's satellite-based broadband service, and continued progress in its ambitious Starship program aimed at lunar and Mars missions.
Unfortunately, it's that coin flip that makes IPO investing terrifying for many investors. While you can always take your chances with a bet on an IPO, there are easier ways, particularly with fund investing. Here are two exchange-traded funds (ETFs) to consider.
First Trust US Equity Opportunities ETF
One, invest in the First Trust US Equity Opportunities ETF (NYSEARCA: FPX).
With an expense ratio of 0.61%, the FPX tracks hot IPOs, giving investors access to new stocks during their initial, most crucial days on the market. By buying it, not only can you avoid paying gobs of money for IPOs that may or may not work out, but you're also being exposed to multiple hot IPOs at the same time at a lesser cost.
In fact, even with some of the most obnoxious IPO failures, the ETF managed to run from a 2009 low of around $11 to a recent high of $171. It's a safer alternative than risking your hard-earned money to another potential coin flip.
With the FPX, it doesn't matter if the stock is hot or a dud; the excitement surrounding IPOs continues to send the FPX to new highs.
Renaissance IPO ETF
Another option is the Renaissance IPO ETF (NYSEARCA: IPO).
With an expense ratio of 0.6%, the ETF provides "investors with the largest, most liquid US-listed newly public company stocks in one security, reducing the risk of single-stock ownership while avoiding overlap with major core indices for optimal diversification across markets and time," as noted by Renaissance Capital.
Since November 2023, the ETF rallied from a low of about $30 to its current price of $48. From here, we'd eventually like to see the ETF rally back to $60 a share, which it last tested in 2022.
Here’s Why the SpaceX IPO Matters
The SpaceX IPO matters not just because of Elon Musk's star power, but because it highlights how emotionally charged IPO investing can become. When a company captures public imagination—whether it's Ferrari, SpaceX, or the next tech disruptor—valuation discipline often takes a back seat. That's when risk quietly rises.
For most investors, the lesson isn't to chase or avoid IPOs entirely, but to rethink how they participate. IPO-focused ETFs offer exposure to innovation, momentum, and growth without tying your financial outcome to a single launch or failure. If SpaceX ultimately delivers a successful IPO, these funds can still benefit. If expectations fall back to Earth, diversification helps soften the blow. In the long run, managing risk often matters more than catching headlines.
This message is a PAID ADVERTISEMENT for NanoViricides, Inc (NYSE:NNVC) from Interactive Offers. StockEarnings, Inc. has received a fixed fee of $8000 from Interactive Offers for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between Dec 19, 2025 and Dec 25, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either NanoViricides, Inc (NYSE:NNVC) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc (NYSE:NNVC) on EQUISCREEN website for additional information about the relationship between Interactive Offers and NanoViricides, Inc (NYSE:NNVC).
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.
StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com
0 Response to "Phase 2 Trials Incoming - Could NNVC Be the Next Biotech Giant?"
Post a Comment